Treatment with statins. Compliance evaluation using reference based DDDs;L'utilizzo delle DDD reference based per la valutazione della compliance terapeutica nel trattamento con statine

PharmacoEconomics - Italian Research Articles

Volumn 10, Issue 2, 2008, Pages 77-88

  Lucioni, Carlo ^a,i   Mazzi, S ^a   Pari, B ^b   Bonello, M ^b   Mazzanti, B ^c   Fresca, G ^c   Fagotti, M ^d   Goretti, M B ^d   Rossi, G ^e   Giuliani, G E ^e   Patregnani, L ^f   Bogino, C ^g   D'Orsi, M ^h   Tinella, M ^h   Zuccotti, G F ^h  

^a Wolters Kluwer Health Italy   (Italy)

^b ASL 14 Veterinary Services   (Italy)

^c ASL 9   (Italy)

^d ASL 3   (Italy)

^e ASL Lecce   (Italy)

^f Servizio Salute Regione Marche

^g Azienda Regionale Sanitaria Regione Marche ^*

^h Public Hospital of Novi Ligure   (Italy)

ⁱ Wolters Kluwer Health Italy Ltd   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; DYSLIPIDEMIA; HUMAN; ITALY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTION; RECOMMENDED DRUG DOSE; TREND STUDY; WORLD HEALTH ORGANIZATION;

EID: 48749095591     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320644     Document Type: Article

References (21)

1. National Center for Chronic Disease Prevention and Health Promotion. Preventing heart disease and stroke (online: www.cdc.gov/nccdphp/ bb_heartdisease/index.htm)
2. Task Force for Compliance. Non compliance with medication regimens: an economic tragedy: emerging issues in pharmaceutical cost containing. Washington, DC: National Pharmaceutical Council, 1994: 1-32
3. Mc Ghan WF, Peterson AM. Pharmacoeconomic impact of non-compliance. Bridgewater, NJ: US Pharmacist Impact, 2001: 3-13
4. Stamler J, Wentwoeth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on primary screens of the Multiple Risk Factor Intervention Trial. Am J Med 1986; 80: 33-9
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
8. The Long-Term Intervention with pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
9. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-33
10. Avorn J, Monett J, Lacour A, et al. Persistence of use lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-62
11. Lucioni C, Mazzi S, Cerra C, et al. Uno studio di drug utilisation delle statine nella recente prassi terapeutica italiana. PharmacoEconomics-Italian Research Articles 2006; 8: 3-17
12. Lucioni C, Mazzi S, Cerra C, Fratino P. Gli Inibitori della Pompa Protonica: uno studio di drug utilization, con particolare riferimento all'appropriatezza del loro uso nella gastroprotezione. Pharmacoeconomics- Italian Research Articles 2007; 9: 75-89
13. http://www.whocc.no/atcddd/
14. Clark KW, Gray D. The Defined Daily Dose as a tool in Pharmacoeconomics. Advantages and limitations. PharmacoEconomics 1995; 7: 280-3
15. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systemic review and meta-analysis. BMJ 2003; 326: 1423-9
16. Grundy SM, Cleeman JI, Noel Bairy Merz C, et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39
17. Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005; 21: 1123-30
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
19. Deambrosis P, Saramin C, Terrazzani G, et al. Dieci anni di utilizzo delle statine: adesione alla terapia e costi del trattamento farmacologico. Pharmacoeconomics-Italian Research Articles 2005; 7: 187-94
20. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60: 543-51
21. Peterson AM, Nau PN, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12